Omalizumab

Anti-IgE monoclonal antibody · also known as Xolair

Anti-IgE monoclonal antibody; reduces free IgE and downregulates the high-affinity IgE receptor on mast cells and basophils.

How it relates to mast cells: MCAS patients
Types of studies cited: Case series , Cohort study
Approved in the US for: allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy
Randomised trials in: chronic spontaneous urticaria, IgE-mediated food allergy

What this relationship means: Studied in people diagnosed with mast cell activation syndrome. Current evidence consists of case reports, uncontrolled series, or retrospective review rather than randomised comparisons — so it establishes that people have taken it, not that it worked. A 2025 practical-management review places this at step 8 of the sequence it describes — described for severe recurrent reactions despite the preceding treatments. That is what the review reports, not a recommendation from this site.

Mechanism of action

Omalizumab binds circulating IgE at the site that would otherwise engage the high-affinity receptor FcεRI, lowering free IgE. Sustained reduction in free IgE leads to downregulation of FcεRI expression on mast cells and basophils, raising the threshold for IgE-mediated degranulation.

Its US label covers allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy — not mast cell activation syndrome. Use in MCAS is off-label.

The two facts on this page are worth holding apart. Omalizumab has randomised, placebo-controlled trials behind it, and those trials are in chronic spontaneous urticaria and in IgE-mediated food allergy. In MCAS itself the published record is uncontrolled. A reader who takes “there are randomised trials” and “this is used for MCAS” and puts them together gets a conclusion neither fact supports.

Sources

Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome Peer-reviewed study 2025 PMID 39741373 · link checked 20 Aug 2026
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria (ASTERIA II) Peer-reviewed study 2013 PMID 23432142 · link checked 21 Aug 2026
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines (ASTERIA I) Peer-reviewed study 2015 PMID 25046337 · link checked 21 Aug 2026
Omalizumab for the Treatment of Multiple Food Allergies (OUtMATCH) Peer-reviewed study 2024 PMID 38407394 · link checked 21 Aug 2026
Xolair (omalizumab) US prescribing information Drug label · link checked 21 Aug 2026
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management Review article 2019 PMID 30961835 · link checked 20 Aug 2026

What this evidence cannot establish

The MCAS literature is case series and retrospective cohorts without control arms, pooled in a 2025 systematic review. In a relapsing-remitting condition, before-and-after data cannot separate a drug effect from spontaneous remission, and the cases that improved are the ones most likely to have been written up. The randomised evidence is real but comes from other conditions, which is why it is shown as a separate fact rather than folded into the same badge.

Registered trials

Phase 2/3 · Completed NCT01333293

mastocytosis · 17 participants enrolled

Read from ClinicalTrials.gov on 22 Aug 2026

What this page does not say

No dosing, and no claim that this works. The entry describes a published mechanism, the cited study types, and what those studies cannot establish — nothing further. Why the site is built this way.

Recently verified. Verified 21 Aug 2026